Abstract
Panicogenic sensitivity to CCK-tetrapeptide (CCK-4) is enhanced in panic disorder patients relative to normal controls (NC). We sought to determine whether CCK-4 sensitivity is augmented in patients with social phobia (SP) (n = 12) and obsessive-compulsive disorder (OCD) (n = 8) versus NC (n = 12). We also determined whether CCK-4 could elicit syndrome-specific symptoms in SP and OCD patients. The study employed a single-blind, placebo-controlled, within-subject design. Behavioral, cardiovascular and hormonal responses to a submaximal dose (20 microg) of CCK-4 were evaluated. Panic frequency after the placebo and CCK-4 challenge varied as a function of diagnosis. Differences in panic frequency between groups and between challenge agents within each group did not, however, reach statistical significance. Further, the number and intensity of panic symptoms, intensity of subjective anxiety, autonomic reactivity and hormonal release after CCK-4 administration did not distinguish the groups. Core symptoms of SP and OCD were unaffected by CCK-4. These data failed to detect significant differences between groups on behavioral, cardiovascular and hormonal response to CCK-4. The lack of effect of CCK-4 on SP and OCD symptoms suggests th...Continue Reading
References
Nov 15, 1992·Biological Psychiatry·J BradwejnC Karkanias
Jul 1, 1991·Archives of General Psychiatry·J BradwejnC Shriqui
Feb 1, 1990·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·J BradwejnG Meterissian
Jan 1, 1987·Psychopharmacology·S A RasmussenD S Charney
Jan 1, 1985·Annals of the New York Academy of Sciences·M Denavit-SaubiéJ Champagnat
Aug 1, 1984·Archives of General Psychiatry·M R LiebowitzS O Davies
Aug 28, 1995·Psychiatry Research·G PernaL Bellodi
Jul 15, 1994·Biological Psychiatry·J L AbelsonA I Vinik
Jan 1, 1995·The American Journal of Psychiatry·G PernaL Bellodi
Apr 1, 1994·Psychopharmacology·H J van MegenM Traub
Jun 1, 1994·Archives of General Psychiatry·J BradwejnH Westenberg
Jun 1, 1993·Trends in Pharmacological Sciences·J HarroJ Bradwejn
Aug 1, 1996·Psychopharmacology·A S de LeeuwH G Westenberg
May 1, 1997·The American Journal of Psychiatry·O Brawman-MintzerJ C Ballenger
Mar 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·U D McCannT W Uhde
Jul 1, 1997·Biological Psychiatry·I M van VlietK L Ho Pian
Sep 29, 1998·Depression and Anxiety·D KoszyckiJ Bradwejn
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J M Le MellédoJ Bradwejn
Apr 15, 1999·Biological Psychiatry·M JavanmardJ Bradwejn
Feb 9, 2000·Biological Psychiatry·M KellnerR Yehuda
Jun 7, 2000·Psychoneuroendocrinology·A J FlintF J Vaccarino
Citations
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Qian ChenYa-Ping Tang
May 4, 2012·Depression and Anxiety·P ZwanzgerJ Bradwejn
Mar 15, 2012·Peptides·Diana KoszyckiJacques Bradwejn
May 18, 2010·Psychiatry Research·Innar TõruJakov Shlik
Jul 16, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowPeter Riederer
Jul 21, 2010·Journal of Psychopharmacology·Berta Garcia de MiguelSimon J C Davies
Apr 17, 2020·Frontiers in Cellular Neuroscience·Xin-Rui Qi, Li Zhang
Aug 23, 2020·Brain Sciences·Matteo VismaraBernardo Dell'Osso
Oct 19, 2020·Journal of Ethnopharmacology·Shao-Nan WangChun-Guo Wang